Randomised controlled pilot feasibility trial of an early intervention programme for young infants with neurodevelopmental impairment in Uganda: a study protocol. Issue 10 (9th October 2019)

• Record Type: Journal Article
• Authors: Nampijja, Margaret; Webb, Emily; Nanyunja, Carol; Sadoo, Samantha; Nalugya, Ruth; Nyonyintono, James; Muhumuza, Anita; Ssekidde, Moses; Katumba, Kenneth; Magnusson, Brooke; Kabugo, Daniel; Cowan, Frances M; Martinez-Biarge, Miriam; Zuurmond, Maria; Morgan, Cathy; Lester, Deborah; Seeley, Janet; Tann, Cally J
• Is Part Of: BMJ open. Volume 9:Issue 10(2019)
• Publication Date: 2019-10-09
• Subjects: neonatal encephalopathy -- Uganda -- outcomes -- impairment -- neurodevelopment -- cohort study; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-032705
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Early intervention programmes (EIPs) for infants with neurodevelopmental impairment have been poorly studied especially in low-income settings. We aim to evaluate the feasibility and acceptability of a group participatory EIP, the 'ABAaNA EIP', for young children with neurodevelopmental impairment in Uganda. Methods and analysis: We will conduct a pilot feasibility, single-blinded, randomised controlled trial comparing the EIP with standard care across two study sites (one urban, one rural) in central Uganda. Eligible infants (n=126, age 6–11 completed months) with neurodevelopmental impairment (defined as a developmental quotient <70 on Griffiths Scales of Mental Development, and, or Hammersmith Infant Neurological Examination score <60) will be recruited and randomised to the intervention or standard care arm. Intervention arm families will receive the 10-modular, peer-facilitated, participatory, community-based programme over 6 months. Recruited families will be followed up at 6 and 12 months after recruitment, and assessors will be blinded to the trial allocation. The primary hypothesis is that the ABAaNA EIP is feasible and acceptable when compared with standard care. Primary outcomes of interest are feasibility (number recruited and randomised at baseline) and acceptability (protocol violation of arm allocation and number of sessions attended) and family and child quality of life. Guided by the study aim, the qualitative data analysis will use a data-led thematic framework approach. The findings will inform scalability and sustainability of the programme. Ethics and dissemination: The trial protocol has been approved by the relevant Ugandan and UK ethics committees. Recruited families will give written informed consent and we will follow international codes for ethics and good clinical practice. Dissemination will be through peer-reviewed publications, conference presentations and public engagement. Trial registration number: ISRCTN44380971 ; protocol version 3.0, 19th February 2018.